BIOTA SECURES US DRUG LICENCE

A A

BIOTA Holdings has announced a licensing and collaboration agreement with US-based MedImmune to develop a product for the treatment and prevention of the respiratory infection RSV disease. The deal supports Biota's persistent claim that it is more than a single-product company involved in a big litigation play.

The Australian (http://www.theaustralian.news.com.au/common/story_page/0,5744,17581755%255E643,00.html)